BTOG 2020 | ALTA-1L: brigatinib vs crizotinib

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, following the first presentation of the study, Dr Newsome-Davis discusses the discusses the ALTA-1L study (NCT02737501) investigating brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.